← Eichor
Study identifier: NCT06016842 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

Condition: Primary Biliary Cholangitis (PBC)  ·  Sponsor: Ipsen

PhasePhase 3
Planned participants276
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment) and will last up to 3.5 years for each participant. The main aim of this study is to determine if elafibranor is better than placebo in preventing clinical outcome events showing disease worsening (including progression of disease leading to liver transplant or death). This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itching and tiredness.

This description comes directly from the study's public registry record.

Talk to the study team

Ipsen Clinical Study Enquiries  ·  See e mail  ·  clinical.trials@ipsen.com

Always discuss trial participation with your own doctor first.

Locations (186)

Arizona Liver HealthTucson, Arizona, United StatesRecruiting
Arkansas Diagnostic Center, PALittle Rock, Arkansas, United StatesTerminated
Southern California Research CenterCoronado, California, United StatesRecruiting
Cedars-Sinai Medical CenterLos Angeles, California, United StatesActive Not Recruiting
GastroIntestinal BioSciencesLos Angeles, California, United StatesRecruiting
University of California Los AngelesLos Angeles, California, United StatesWithdrawn
University of California Davis Medical CenterSacramento, California, United StatesRecruiting
University of ColoradoAurora, Colorado, United StatesRecruiting
Peak Gastroenterology AssociatesColorado Springs, Colorado, United StatesRecruiting
South Denver Gastroenterology, P.C.Englewood, Colorado, United StatesRecruiting
Rocky Mountain GastroenterologyLittleton, Colorado, United StatesRecruiting
University Of Miami School Of Medicine, Center For Liver DiseasesMiami, Florida, United StatesRecruiting

+ 174 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06016842